Glutathione: Chemical Forms, Human Research, and FDA Compounding Status

Last evidence review: August 27, 2026

Glutathione is an endogenous tripeptide involved in cellular redox chemistry. FDA’s substance record identifies reduced glutathione as L-gamma-glutamyl-L-cysteinylglycine and assigns it UNII GAN16C9B8O.[1]

The word “glutathione” can conceal important differences. Reduced glutathione, commonly called GSH, is not the same chemical form as oxidized glutathione, commonly called GSSG. Salts and derivatives are also distinct. Oral, topical, intranasal, inhaled, injectable, and other formulations cannot be treated as one evidence record.

This page reviews chemical identity, selected controlled human studies, current FDA compounding status, and a recent quality alert. It does not provide medical advice or instructions for using any product.

Identity at a glance

A UNII identifies a substance. It does not establish a clinical claim or verify a commercial material.

Why do reduced and oxidized glutathione need separate records?

Reduced glutathione is commonly abbreviated GSH. Its oxidized disulfide form is GSSG. PubChem records them separately: reduced glutathione has formula C10H17N3O6S, while glutathione disulfide has formula C20H32N6O12S2. Their molecular masses consequently differ. Reduced glutathione record, glutathione disulfide record.

This matters whenever a report gives an amount or a ratio. A measurement of reduced glutathione is not a measurement of every glutathione-related species. A total-glutathione assay may have a definition that depends on its treatment of oxidized or protein-bound material. The assay’s definition must accompany the number.

Similarly, a ratio can change because its numerator rises, its denominator falls, or both happen. The same ratio can therefore conceal different absolute concentrations. Describing all of these situations as increased glutathione loses information that may determine the biological interpretation.

A salt designation concerns chemical composition and amount basis. A description such as liposomal or micellar concerns the formulation. Neither replaces the name of the underlying substance. Two products using the same delivery-system word may still have different ingredients, physical characteristics and stability.

A product page should therefore state the exact form, gamma-glutamyl linkage, stereochemistry, salt status, formula, molecular mass, assay basis, and lot identity. A generic “glutathione” label is not enough to connect a commercial sample to a study.

What does its cellular role establish?

FDA’s scientific evaluation describes endogenous glutathione synthesis and its role in cellular redox systems.[2] That supports a narrow biochemical statement about the molecule.

It does not establish that an external glutathione product produces a clinical outcome. Terms such as “detox,” “immune support,” “anti-aging,” “skin brightening,” and “cellular protection” require direct evidence for the exact form, route, population, comparator, duration, and endpoint.

Evidence tier: E, Laboratory evidence for a particular mechanism. A biochemical role is not a clinical-effect claim.

What did controlled oral studies find?

Two small randomized, double-blind, placebo-controlled studies in healthy adults reported different biomarker findings under different study designs.

A four-week randomized trial in healthy adults found no significant differences in the reported glutathione-status and oxidative-stress measurements. A separate six-month study reported increases in several glutathione compartments among its analyzed participants. These were different experiments, not two interchangeable measurements of a single universal response. Four-week primary abstract, six-month primary abstract.

The longer study’s favorable laboratory findings do not turn the shorter study positive. Nor does the shorter study establish that every formulation is incapable of producing a biochemical response. Duration, material, assay definitions and analysis populations can all affect what comparison is being made.

Evidence tier: C, Limited and partly inconsistent human biomarker evidence.

What did the Parkinson disease pilot trials find?

A randomized, double-blind intravenous pilot enrolled 21 participants and found no significant between-group difference on the reported Parkinson rating-scale outcomes.[5]

A later double-blind intranasal phase 2b study enrolled 45 participants. All groups improved during the study, and neither glutathione group was superior to placebo on the reported clinical outcome.[6]

These were small studies using different formulations and routes. They do not establish a neurologic indication, validate a lyophilized powder, or support combining route-specific evidence.

Evidence tier: C, Limited human evidence, with null superiority findings on the described clinical endpoints.

What is the current FDA compounding status?

FDA’s May 14, 2026 category document lists glutathione in 503A Category 1, which means the bulk substance is under evaluation.[7] Category 1 does not mean that FDA approved glutathione, placed it on a final bulks list, endorsed a formulation, or found it safe or effective.

In 2022, FDA staff recommended against adding glutathione to the 503A bulks list after considering the evaluation criteria. The advisory committee subsequently voted eight in favor, five against and one abstaining on adding it. Neither event was a drug-product approval. FDA staff presentation, advisory committee summary.

CDC’s September 2026 investigation page states that there are no FDA-approved glutathione products in the United States. It also distinguishes dietary-supplement-grade ingredients from those appropriate for injectable preparations. CDC investigation and background.

That is a dated US statement, not an assessment of every jurisdiction. It should not be expanded into a claim about worldwide availability or a personalized legal conclusion concerning a particular practice.

What does FDA’s August 2026 glutathione alert say?

On August 27, 2026, FDA reported adverse events involving at least 30 patients after compounded injectable products made with dietary-supplement-grade glutathione from an identified supplier lot. FDA said that grade was not appropriate for making injectable drugs and emphasized supplier qualification and quality built into production.[9]

CDC’s September update separately described reports involving more than 25 people in at least four states, including three hospitalizations, while emphasizing that the investigation was ongoing. These agency counts should not be added together or treated as a reconciled case series. CDC investigation update.

The notice did not identify or test Serum Research material. It must not be cited as evidence that a Serum Research lot was involved, contaminated, safe, or unsafe. Its relevance to this page is the product-quality principle: ingredient grade, intended route, supplier, manufacturing controls, and lot traceability cannot be inferred from a name or a certificate headline.

Status checked: August 27, 2026. Recheck the FDA notice for updates before publication.

Important evidence limits

• Reduced GSH and oxidized GSSG are different chemical forms.
• Evidence from one route or formulation does not establish another.
• Biomarker changes do not automatically represent a health outcome.
• The small controlled studies have inconsistent or null findings on several key measures.
• Category 1 compounding status is not FDA approval or endorsement.
• The current FDA alert concerns specified compounded products and supplier material, not a Serum Research lot.
• No cited source establishes the identity, quantity, purity, sterility, stability, or performance of a Serum Research material.

Frequently asked questions

Are GSH and GSSG the same?

No. GSH refers to reduced glutathione, while GSSG is the oxidized form. They are related but chemically distinct and should not share an undifferentiated evidence claim.

Does glutathione’s antioxidant role prove a product benefit?

No. An endogenous biochemical role does not by itself show that an external product changes a patient-centered outcome.

Is glutathione FDA approved because it appears in Category 1?

No. FDA Category 1 means a nominated bulk substance is under evaluation. It is not an approval, endorsement, or final-list decision.

What did the oral trials find?

One short controlled study found no significant biomarker change, while a longer small study reported increases in several glutathione measures. The outcomes were biomarkers, and the evidence is limited and partly inconsistent.

Did the Parkinson trials show superiority over placebo?

The cited intravenous pilot found no significant between-group difference, and the cited intranasal phase 2b study reported that neither glutathione group was superior to placebo on the clinical outcome.

Did FDA’s August 2026 alert involve Serum Research?

The FDA notice identified specific compounded products and supplier material. It did not identify or test a Serum Research product, so it cannot support a claim about a Serum Research lot.

Does this page explain how to use glutathione?

No. It is an identity, evidence, and regulatory-status summary and intentionally contains no personal-use instructions.

Primary and official sources

1. FDA GSRS glutathione identity record, GAN16C9B8O
2. FDA 2022 glutathione evaluation
3. Four-week oral biomarker trial, PMID 21875351
4. Six-month oral biomarker trial, PMID 24791752
5. Intravenous Parkinson pilot, PMID 19230029
6. Intranasal Parkinson phase 2b study, PMID 28436395
7. FDA 503A bulk-substance category document, May 14, 2026
8. FDA PCAC vote summary
9. FDA August 27, 2026 glutathione alert

Suggested internal links after publication: Research Library hub; how we review evidence; approved drug versus research material; quality testing; certificates. No catalog link until the gate below passes.